Publication: Neuroblastoma-associated opsoclonus-myoclonus-ataxia syndrome: an important yet overlooked diagnosis in pediatric ataxia
Loading...
Program
Organization Authors
Co-Authors
Kebudi, Rejin
Date
Language
eng
Type
Embargo Status
No
Journal Title
Journal ISSN
Volume Title
Alternative Title
Abstract
Background. Opsoclonus-myoclonus-ataxia syndrome (OMAS) is a rare, immune-mediated neurological disorder, often associated with neuroblastoma (NB) in children. This study aimed to describe the clinical features, diagnostic challenges, treatment, and outcomes of pediatric patients with NB-associated OMAS. Methods. We retrospectively reviewed medical records of seven children diagnosed with NB-associated OMAS between November 1, 2015 and January 31, 2025. Data on demographics, clinical presentation, tumor characteristics, treatment protocols, relapses, and outcomes were collected. The Mitchell-Pike OMS Rating Scale was used to assess severity. Results. The cohort included four girls and three boys, aged 18-36 months (median 31). All had a history of infection and/or vaccination preceding symptom onset. Ataxia was the most common initial symptom (6/7, 85.7%), followed by behavioral disturbances and sleep disorders (5/7, 71.4% each). At presentation, opsoclonus was present in two patients, which was initially misdiagnosed as nystagmus. All but one patient had opsoclonus during the disease course. Neuroblastomas were located in abdominal (n=4), thoracic (n=1), and sacral (n=2) regions
all tumors measured <50 mm and were stage L1. First-line treatment included tumor resection, intravenous immunoglobulin, and corticosteroids. Three patients required second-line therapy (rituximab, cyclophosphamide, mycophenolate mofetil, or azathioprine). After a median follow-up of 40 months (range 26-64), four patients had no neurological sequelae
three had mild cognitive impairment. Conclusion. NB-associated OMAS may present with non-specific symptoms, leading to diagnostic delays. Early recognition, thorough tumor screening, and prompt immunotherapy may improve neurological outcomes. Clinicians should suspect NB in children presenting with ataxia and behavioral/sleep disturbances, even in the absence of opsoclonus or abnormal findings on initial imaging.
all tumors measured <50 mm and were stage L1. First-line treatment included tumor resection, intravenous immunoglobulin, and corticosteroids. Three patients required second-line therapy (rituximab, cyclophosphamide, mycophenolate mofetil, or azathioprine). After a median follow-up of 40 months (range 26-64), four patients had no neurological sequelae
three had mild cognitive impairment. Conclusion. NB-associated OMAS may present with non-specific symptoms, leading to diagnostic delays. Early recognition, thorough tumor screening, and prompt immunotherapy may improve neurological outcomes. Clinicians should suspect NB in children presenting with ataxia and behavioral/sleep disturbances, even in the absence of opsoclonus or abnormal findings on initial imaging.
Source
Publisher
Turkish Journal of Pediatrics
Subject
Citation
item.page.haspartof
Source
Turkish Journal of Pediatrics
item.page.ispartofseries
item.page.edition
DOI
10.24953/turkjpediatr.2026.6821
item.page.datauri
item.page.link
Rights
N/A
